Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as satavaptan (SR121463B), SR121463B
satavaptan · 8 trials · 6 indications
| Arm | Type | Description |
|---|---|---|
| Satavaptan | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Satavaptan | DRUG | oral administration once daily |
| placebo | DRUG | oral administration once daily |
| SR121463B | DRUG | - |
| satavaptan (SR121463B) | DRUG | - |
Inclusion Criteria: * Participants with cirrhosis of the liver * Participants with clinically evident ascites primarily managed by diet and/or diuretics * Stable treatment of ascites for at least the previous 2 weeks without paracentesis * Participants having undergone no more than one therapeutic ...
Satavaptan is an investigational small molecule developed for ascites, including cirrhotic ascites, and for the syndrome of inappropriate antidiuretic hormone secretion (SIADH). It has been studied in patients with ascites due to liver cirrhosis, both with and without low sodium levels, and in the prevention of ascites.
Satavaptan targets AVPR2, the vasopressin V2 receptor. It acts as an antagonist at this receptor, meaning it blocks the receptor's activity. This mechanism is relevant to conditions involving fluid retention and low sodium levels, such as ascites and SIADH.
Satavaptan is being developed by Sanofi, which trades under the ticker SNY. Sanofi is the sponsor of the clinical trials evaluating satavaptan in patients with ascites and related conditions.
Satavaptan has been studied in Phase 3 clinical development. A Phase 3 trial, the CATS study, has been completed. The drug is investigational and has not been approved by the FDA for any indication.
Satavaptan has been evaluated in four completed clinical trials. These include the Phase 3 CATS trial (NCT00358878) in cirrhotic ascites, and three Phase 2 dose-ranging studies: NCT00501722 in hyponatraemic patients, NCT00501566 in normonatraemic patients, and NCT00501384 for the prevention of ascites.
Yes, satavaptan is also known as SR121463B. SR121463B is an alternative identifier for the same investigational drug developed by Sanofi.